Bala B Oven Ustaalioglu1, Ahmet Bilici2, Burçak E Yilmaz1, Mehmet Aliustaoglu1, Mesut Seker3, Fugen Vardar4, Mahmut Gumus3. 1. Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey. 2. Department of Medical Oncology, Medipol University, Istanbul, Turkey. 3. Department of Medical Oncology, Kartal Education and Research Hospital, Istanbul, Turkey. 4. Department of Pathology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
Abstract
INTRODUCTION: In Turkey, the gene expression profile test is not standard, so adjuvant treatment is planned according to clinicopathological factors. Therefore, we retrospectively analyzed important parameters that affect the decision on adjuvant chemotherapy, and also factors related to survival in stage IA breast cancer patients in Turkey. METHODS: We retrospectively evaluated 347 stage IA patients. The relationship between the clinicopathological parameters and adjuvant chemotherapy was analyzed. RESULTS: The median age and follow-up time were 52 years (range: 25-86) and 22.6 months (range: 1-113), respectively. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 87.9% and 98.7%, respectively, but the median DFS was not reached. Age, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, and the presence of triple-negative breast tumor (TNBC) were related to DFS, and lymphovascular invasion (LVI), perineural invasion (PNI), HER2 status, the presence of TNBC, and recurrence were related to OS (p > 0.05). Furthermore, age, menopausal status, multicentricity, grade, tumor size, necrosis, ER, the presence of TNBC, and HER2 were found to be related to adjuvant therapy decision (p > 0.05). All these parameters, in addition to LVI and PNI, were independent factors for chemotherapy by logistic regression analysis. CONCLUSIONS: In decisions about adjuvant therapy in stage IA breast cancer patients, clinicopathological factors should be kept in mind.
INTRODUCTION: In Turkey, the gene expression profile test is not standard, so adjuvant treatment is planned according to clinicopathological factors. Therefore, we retrospectively analyzed important parameters that affect the decision on adjuvant chemotherapy, and also factors related to survival in stage IA breast cancerpatients in Turkey. METHODS: We retrospectively evaluated 347 stage IA patients. The relationship between the clinicopathological parameters and adjuvant chemotherapy was analyzed. RESULTS: The median age and follow-up time were 52 years (range: 25-86) and 22.6 months (range: 1-113), respectively. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 87.9% and 98.7%, respectively, but the median DFS was not reached. Age, estrogen receptor (ER) status, humanepidermal growth factor receptor 2 (HER2) status, and the presence of triple-negative breast tumor (TNBC) were related to DFS, and lymphovascular invasion (LVI), perineural invasion (PNI), HER2 status, the presence of TNBC, and recurrence were related to OS (p > 0.05). Furthermore, age, menopausal status, multicentricity, grade, tumor size, necrosis, ER, the presence of TNBC, and HER2 were found to be related to adjuvant therapy decision (p > 0.05). All these parameters, in addition to LVI and PNI, were independent factors for chemotherapy by logistic regression analysis. CONCLUSIONS: In decisions about adjuvant therapy in stage IA breast cancerpatients, clinicopathological factors should be kept in mind.
Entities:
Keywords:
Adjuvant therapy; Breast cancer; Chemotherapy; Stage IA
Authors: Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Gordon F Schwartz; Jorge Reis-Fihlo; Lajos Pusztai; Ian S Fentiman; Roland Holland; Harry Bartelink; Emiel J T Rutgers; Lawrence J Solin; Juan Palazzo Journal: Cancer Date: 2012-03-05 Impact factor: 6.860
Authors: Alice Y Ho; Gaorav Gupta; Tari A King; Carmen A Perez; Sujata M Patil; Katherine H Rogers; Yong Hannah Wen; Edi Brogi; Monica Morrow; Clifford A Hudis; Tiffany Traina; Beryl McCormick; Simon N Powell; Mark E Robson Journal: Cancer Date: 2012-03-05 Impact factor: 6.860
Authors: Rachel L Theriault; Jennifer K Litton; Elizabeth A Mittendorf; Huiqin Chen; Funda Meric-Bernstam; Mariana Chavez-Macgregor; Phuong K Morrow; Wendy A Woodward; Aysegul Sahin; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Clin Breast Cancer Date: 2011-07-20 Impact factor: 3.225
Authors: Abenaa M Brewster; Gabriel N Hortobagyi; Kristine R Broglio; Shu-Wan Kau; Cesar A Santa-Maria; Banu Arun; Aman U Buzdar; Daniel J Booser; Vincente Valero; Melissa Bondy; Francisco J Esteva Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Heikki Joensuu; Jorma Isola; Mikael Lundin; Tiina Salminen; Kaija Holli; Vesa Kataja; Liisa Pylkkänen; Taina Turpeenniemi-Hujanen; Karl von Smitten; Johan Lundin Journal: Clin Cancer Res Date: 2003-03 Impact factor: 12.531
Authors: T Gamucci; A Vaccaro; F Ciancola; L Pizzuti; I Sperduti; L Moscetti; F Longo; M A Fabbri; M A Giampaolo; L Mentuccia; L Di Lauro; P Vici Journal: J Cancer Res Clin Oncol Date: 2013-02-15 Impact factor: 4.553